Long-acting injectable risperidone for the treatment of schizophrenia: Clinical perspectives

Drugs

Volumn 67, Issue 11, 2007, Pages 1541-1566

  Möller, Hans Jürgen ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; FLUPENTIXOL; HALOPERIDOL; HALOPERIDOL DECANOATE; LONG ACTING DRUG; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; ZUCLOPENTHIXOL;

AGITATION; AKATHISIA; ANXIETY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED STUDY; COST CONTROL; DEPRESSION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EXTRAPYRAMIDAL SYMPTOM; EXTRAPYRAMIDAL SYNDROME; HEADACHE; HUMAN; HYPERPROLACTINEMIA; INJECTION PAIN; INJECTION SITE PAIN; INSOMNIA; LOW DRUG DOSE; METABOLIC SYNDROME X; PROLACTIN BLOOD LEVEL; PSYCHOSIS; REVIEW; RHINITIS; SCHIZOPHRENIA; SIDE EFFECT; SKIN INDURATION; TARDIVE DYSKINESIA; TREATMENT REFUSAL; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; HUMANS; INJECTIONS; PATIENT COMPLIANCE; RISPERIDONE; SCHIZOPHRENIA;

EID: 34547939340     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767110-00003     Document Type: Review

References (97)

1. Möller HJ, Bartender R, Groß A, et al. The Kraepelinian dichotomy: preliminary results of a 15-year follow-up study on functional psychoses. Focus on negative symptoms. Schizophr Res 2002; 56: 87-94
2. Möller HJ. Course and long-term treatment of schizophrenic psychoses. Pharmacopsychiatry 2004; 37 Suppl. 2: 126-35
3. Möller HJ. Definition, psychopharmacological basis and clinical evaluation of novel/atypical neuroleptics: methodological issues and clinical consequences. World J Biol Psychiatry 2000; 1: 75-91
4. Möller HJ. Antipsychotic agents: gradually improving treatment from the traditional oral neuroleptics to the first atypical depot. Eur Psychiatry 2005; 20: 379-85
5. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995; 21: 419-29
6. Leucht S, Barnes T, Kissling W, et al. Relapse prevention in schizophrenia with new antipsychotics: a meta-analysis of randomized controlled trials. Am J Psychiatry 2003; 160: 1209-22
7. Bhanji NH, Chouinard G, Margolese HC. A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia. Eur Neuropsychopharmacol 2004; 14: 87-92
8. Dolder CR, Lacro JP, Dunn LB, et al. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry 2002; 159: 103-8
9. Möller HJ. Neuroleptische Langzeittherapie schizophrener Erkrankungen. In: Heinrich K, editor. Leitlinien neuroleptischer Therapie. Berlin: Springer, 1990: 97-115
10. Davis JM, Matalon L, Watanabe MD, et al. Depot antipsychotic drugs: place in therapy. Drugs 1994; 47: 741-73
11. Adams CE, Fenton MK, Quraishi S, et al. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br J Psychiatry 2001; 179: 290-9
12. Kane JM. Dosing issues and depot medication in the maintenance treatment of schizophrenia. Int Clin Psychopharmacol 1995; 10 Suppl. 3: 65-71
13. Patel MX, Nikolaou V, David AS. Psychiatrists' attitudes to maintenance medication for patients with schizophrenia. Psychol Med 2003; 33: 83-9
14. Ereshefsky L, Mannaert E. Pharmacokinetic profile and clinical efficacy of long-acting risperidone: potential benefits of combining an atypical antipsychotic and a new delivery system. Drugs R D 2005; 6: 129-37
15. Möller HJ, Kissling W. Advantages and disadvantages of depot-neuroleptics as maintenance medication for chronic schizophrenics. Clin Neuropharmacol 1986; 9 Suppl. 4: 259-62
16. Gerlach J. Depot neuroleptics in relapse prevention: advantages and disadvantages. Int Clin Psychopharmacol 1995; 9 Suppl. 5: 17-20
17. Midha KK, Hubbard JW, Marder SR, et al. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia. J Psychiatry Neurosci 1994; 19: 254-64
18. Glazer WM. Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. J Clin Psychiatry 2000; 61 Suppl. 4: 15-20
19. Chouinard G, Annable L, Ross-Chouinard A, et al. Factors related to tardive dyskinesia. Am J Psychiatry 1979; 136: 79-82
20. Llorca PM, Chereau I, Bayle FJ, et al. Tardive dyskinesias and antipsychotics: a review. Eur Psychiatry 2002; 17: 129-38
21. Chouinard G. Effects of risperidone in tardive dyskinesia: an analysis of the Canadian multicenter risperidone study. J Clin Psychopharmacol 1995; 15: 36-44S
22. Gerlach J. Improving outcome in schizophrenia: the potential importance of EPS and neuroleptic dysphoria. Ann Clin Psychiatry 2002; 14: 47-57
23. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004; 161: 414-25
24. Möller HJ. Risperidone: a review. Expert Opin Pharmacother 2005; 6: 803-18
25. Hamner M. The effects of atypical antipsychotics on serum prolactin levels. Ann Clin Psychiatry 2002; 14: 163-73
26. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002; 346: 16-22
27. Ramstack M, Grandolfi GP, Mannaert E, et al. Long-acting risperidone: prolonged-release injectable delivery of risperidone using medisorb microsphere technology. Schizophr Res 2003; 60 Suppl. 1: 87
28. Eerdekens M, Van Hove I, Remmerie B, et al. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res 2004; 70: 91-100
29. Nordstrom AL, Farde L, Wiesel FA, et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry 1993; 33: 227-35
30. Ereshefsky L, Lacombe S. Pharmacological profile of risperidone. Can J Psychiatry 1993; 38 Suppl. 3: S80-8
31. Gefvert O, Eriksson B, Persson P, et al. Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. Int J Neuropsychopharmacol 2005; 8: 27-36
32. Wilson WH. A visual guide to expected blood levels of long-acting injectable risperidone in clinical practice. J Psychiatr Pract 2004; 10: 393-401
33. Möller HJ, Llorca PM, Sacchetti E, et al. Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies. Int Clin Psychopharmacol 2005; 20: 121-30
34. Parellada E, Andrezina R, Milanova V, et al. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable. J Psychopharmacol 2005; 19: 5-14
35. Mohl A, Westlye K, Opjordsmoen S, et al. Long-acting risperidone in stable patients with schizoaffective disorder. J Psychopharmacol 2005; 19: 22-31
36. Kissling W, Heres S, Lloyd K, et al. Direct transition to long-acting risperidone: analysis of long-term efficacy. J Psychopharmacol 2005; 19: 15-21
37. Rubio G, Martinez I, Ponce G, et al. Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. Can J Psychiatry 2006; 51: 531-9
38. Gastpar M, Masiak M, Latif MA, et al. Sustained improvement of clinical outcome with risperidone long-acting injectable in psychotic patients previously treated with olanzapine. J Psychopharmacol 2005; 19: 32-8
39. Turner M, Eerdekens E, Jacko M, et al. Long-acting injectable risperidone: safety and efficacy in stable patients switched from conventional depot antipsychotics. Int Clin Psychopharmacol 2004; 19: 241-9
40. Chue P, Eerdekens M, Augustyns I, et al. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol 2005; 15: 111-7
41. Lasser RA, Bossie CA, Gharabawi GM, et al. Remission in schizophrenia: results from a 1-year study of long-acting risperidone injection. Schizophr Res 2005; 77: 215-27
42. Fleischhacker WW, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003; 64: 1250-7
43. Gharabawi GM, Lasser RA, Bossie CA, et al. Insight and its relationship to clinical outcomes in patients with schizophrenia or schizoaffective disorder receiving long-acting risperidone. Int Clin Psychopharmacol 2006; 21: 233-40
44. Chue P, Llorca PM, Duchesne I, et al. Hospitalization rates in patients during long-term treatment with long-acting risperidone injection. J Appl Res 2005; 5: 266-74
45. Fleischhacker WW, Rabinowitz J, Kemmler G, et al. Perceived functioning, well-being and psychiatric symptoms in patients with stable schizophrenia treated with long-acting risperidone for 1 year. Br J Psychiatry 2005; 187: 131-6
46. Gharabawi GM, Bossie CA, Zhu Y, et al. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study. Schizophr Res 2005; 77: 129-39
47. Lindenmayer JP, Jarboe K, Bossie CA, et al. Minimal injection site pain and high patient satisfaction during treatment with long-acting risperidone. Int Clin Psychopharmacol 2005; 20: 213-21
48. Lasser RA, Bossie CA, Gharabawi GM, et al. Clinical improvement in 336 stable chronically psychotic patients changed from oral to long-acting risperidone: a 12-month open trial. Int J Neuropsychopharmacol 2005; 8: 427-38
49. Lasser R, Bossie CA, Gharabawi G, et al. Efficacy and safety of long-acting risperidone in stable patients with schizoaffective disorder. J Affect Disord 2004; 83: 263-75
50. Leal A, Rosillon D, Mehnert A, et al. Healthcare resource utilization during 1-year treatment with long-acting, injectable risperidone. Pharmacoepidemiol Drug Saf 2004; 13: 811-6
51. Lasser RA, Bossie CA, Zhu Y, et al. Efficacy and safety of long-acting risperidone in elderly patients with schizophrenia and schizoaffective disorder. Int J Geriatr Psychiatry 2004; 19: 898-905
52. van Os J, Bossie CA, Lasser RA. Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone. Int Clin Psychopharmacol 2004; 19: 229-32
53. Lasser RA, Bossie CA, Gharabawi GM, et al. Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. Eur Psychiatry 2004; 19: 219-25
54. Kane JM, Eerdekens M, Lindenmayer JP, et al. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry 2003; 160: 1125-32
55. Ciliberto N, Bossie CA, Urioste R, et al. Lack of impact of race on the efficacy and safety of long-acting risperidone versus placebo in patients with schizophrenia or schizoaffective disorder. Int Clin Psychopharmacol 2005; 20: 207-12
56. Lauriello J, McEvoy JP, Rodriguez S, et al. Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia. Schizophr Res 2005; 72: 249-58
57. Nasrallah HA, Duchesne I, Mehnert A, et al. Health-related quality of life in patients with schizophrenia during treatment with long-cfu injectable risperidone. J Clin Psychiatry 2004; 65: 531-6
58. Lindenmayer JP, Eerdekens E, Berry SA, et al. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics. J Clin Psychiatry 2004; 65: 1084-9
59. Simpson GM, Mahmoud RA, Lasser RA, et al. A 1-year double-blind study of 2 doses of long-acting risperidone in stable patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry 2006; 67: 1194-203
60. Bai YM, Chen TT, Wu B, et al. A comparative efficacy and safety study of long-acting risperidone injection and risperidone oral tablets among hospitalized patients: 12-week randomized, single-blind study. Pharmacopsychiatry 2006; 39: 135-41
61. Taylor DM, Young C, Patel MX. Prospective 6-month follow-up of patients prescribed risperidone long-acting injection: factors predicting favourable outcome. Int J Neuropsychopharmacol 2006; 9: 685-94
62. Young CL, Taylor DM. Health resource utilization associated with switching to risperidone long-acting injection. Acta Psychiatr Scand 2006; 114: 14-20
63. Chouinard G, Ross-Chouinard A, Annable L, et al. Extrapyramidal Symptom Rating Scale. Can J Neurol Sci 1980; 7: 233
64. Andreasen NC, Carpenter WT Jr, Kane JM, et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 2005; 162: 441-9
65. Taylor DM, Young CL, Mace S, et al. Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients. J Clin Psychiatry 2004; 65: 1076-83
66. Patel MX, Young C, Samele C, et al. Prognostic indicators for early discontinuation of risperidone long-acting injection. Int Clin Psychopharmacol 2004; 19: 233-9
67. Lambert M, Naber D. Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life. CNS Drugs 2004; 18 Suppl. 2: 5-17; discussion 43
68. Möller HJ. State of the art of drug treatment of schizophrenia and the future position of the novel/atypical antipsychotics. World J Biol Psychiatry 2000; 1: 204-14
69. Falkai P, Wobrock T, Lieberman J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: acute treatment of schizophrenia. World J Biol Psychiatry 2005; 6: 132-91
70. Falkai P, Wobrock T, Lieberman J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. World J Biol Psychiatry 2006; 7: 5-40
71. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686-96
72. Anonymous. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27: 596-601
73. Möller HJ. Long-acting risperidone: focus on safety. Clin Ther 2006; 28: 633-51
74. Scandinavian Society of Psychopharmacology Committee of Clinical Investigations. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. Acta Psychiatr Scand Suppl 1987; 334: 81-94
75. Love RC, Nelson MW. Pharmacology and clinical experience with risperidone. Expert Opin Pharmacother 2000; 1: 1441-53
76. Liu GG, Sun SX, Christensen DB, et al. Cost comparisons of olanzapine and risperidone in treating schizophrenia. Ann Pharmacother 2004; 38: 134-41
77. Shaw JW. Economic evaluations of olanzapine and risperidone. Am J Health Syst Pharm 2002; 59: 1366-75
78. Revicki DA. Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia. Schizophr Res 1999; 35 Suppl.: S101-9
79. Zito JM. Pharmacoeconomics of the new antipsychotics for the treatment of schizophrenia. Psychiatr Clin North Am 1998; 21: 181-202
80. Davies A, Langley PC, Keks NA, et al. Risperidone versus haloperidol: II. Cost-effectiveness. Clin Ther 1998; 20: 196-213
81. Foster RH, Goa KL. Risperidone: a pharmacoeconomic review of its use in schizophrenia. Pharmacoeconomics 1998; 14: 97-133
82. Remington G, Devos E, Eerdekens M, et al. Treatment with long-acting risperidone injection reduces healthcare resource use. Int J Neuropsychopharmacol 2002; 5 Suppl. 1: S189
83. Chue PS, Devos E, Duchesne IY, et al. One year hospitalization rates in patients with schizophrenia during long-term treatment with long-acting risperidone. Value Health 2002; 5: 229
84. Llorca PM, Devos E, Eerdekens M, et al. Re-hospitalization rates with long-acting risperidone injection are lower than those reported for other antipsychotics. Int J Neuropsychopharmacol 2002; 5 Suppl. 1: S189
85. Eriksson L, Almqvist A, Mehnert A, et al. Long-acting risperidone significantly reduces the need for institutional psychiatric care. Poster at the American College of Neuropsychopharmacology 42nd Annual Meeting; 2003 Dec 7-11; San Juan
86. Llorca PM, Jasso-Mosqueda JG, Miadi-Fargier H, et al. Long-acting risperidone injection in patients with schizophrenia compared with oral olanzapine and haloperidol decanoate: results of a cost-effectiveness model. Poster presented at the 16th European College of Neuropsychopharmacology Congress; 2003 Sep 20-24; Prague
87. Rabinowitz J, Lichtenberg P, Kaplan Z, et al. Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am J Psychiatry 2001; 158: 266-9
88. Heeg BM, van Aalst G, van den Arend IJ, et al. A discrete events model of long-term outcomes and cost of treatment with long-acting risperidone in schizophrenia. Value Health 2002; 5: 515-6
89. Heeg BM, Emmermann A, Laux G, et al. Costs and effects of Risperdal Consta™ in comparison to conventional depot and short-acting atypical formulations in Germany. Value Health 2003; 6: 692
90. Harrison TS, Goa KL. Long-acting risperidone: a review of its use in schizophrenia. CNS Drugs 2004; 18: 113-32
91. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-23
92. Coldham EL, Addington J, Addington D. Medication adherence of individuals with a first episode of psychosis. Acta Psychiatr Scand 2002; 106: 286-90
93. Kamali M, Kelly BD, Clarke M, et al. A prospective evaluation of adherence to medication in first episode schizophrenia. Eur Psychiatry 2006; 21: 29-33
94. Wobrock T, Sittinger H, Behrendt B, et al. Comorbid substance abuse and neurocognitive function in recent-onset schizophrenia. Eur Arch Psychiatry Clin Neurosci. Epub 2006 Nov 25
95. Marder SR, Conley R, Ereshefsky L, et al. Clinical guidelines: dosing and switching strategies for long-acting risperidone. J Clin Psychiatry 2003; 64 Suppl. 16: 41-6
96. Keith SJ, Pani L, Nick B, et al. Practical application of pharmacotherapy with long-acting risperidone for patients with schizophrenia. Psychiatr Serv 2004; 55: 997-1005
97. Masand PS, Gupta S. Long-acting injectable antipsychotics in the elderly: guidelines for effective use. Drugs Aging 2003; 20: 1099-110